Adriamycin pfs and Conjunctivitis exacerbated - a phase IV clinical study of FDA data

Summary:

Conjunctivitis exacerbated is reported as a side effect among people who take Adriamycin pfs (doxorubicin hydrochloride), especially for people who are female, 30-39 old, also take Cytoxan, and have Vitiligo.

The phase IV clinical study analyzes which people have Conjunctivitis exacerbated when taking Adriamycin pfs. It is created by eHealthMe based on reports of 6,484 people who have side effects when taking Adriamycin pfs from the FDA, and is updated regularly.

What is Adriamycin pfs?

Adriamycin pfs has active ingredients of doxorubicin hydrochloride. eHealthMe is studying from 6,495 Adriamycin pfs users. Check the latest studies of Adriamycin pfs.

What is Conjunctivitis exacerbated?

Conjunctivitis exacerbated (bad situation of conjunctivitis) is found to be associated with 1,068 drugs and 426 conditions by eHealthMe. Check the latest studies of Conjunctivitis exacerbated.

On Jul, 13, 2026

6,484 people reported to have side effects when taking Adriamycin pfs.
Among them, 59 people (0.91%) have Conjunctivitis exacerbated.

Could Adriamycin pfs cause Conjunctivitis exacerbated?

Among these 59 people:

What is the gender of people who have Conjunctivitis exacerbated when taking Adriamycin pfs? *

female: 57.63 %
male: 42.37 %

What is the age of people who have Conjunctivitis exacerbated when taking Adriamycin pfs? *

What are other drugs people take besides Adriamycin pfs? *

What are other side effects people have besides Conjunctivitis exacerbated? *

Anaemia (lack of blood): 37 people, 62.71%
Sinusitis (inflammation of sinus): 35 people, 59.32%
Stress And Anxiety: 34 people, 57.63%
Back Pain: 32 people, 54.24%
Pain: 31 people, 52.54%
Osteonecrosis Of Jaw (death of bone of jaw): 29 people, 49.15%
Osteopenia (a condition where bone mineral density is lower than normal): 28 people, 47.46%
Headache (pain in head): 28 people, 47.46%
Depression: 27 people, 45.76%
Neuropathy Peripheral (surface nerve damage): 25 people, 42.37%

What are the existing conditions these people have? *

Vitiligo (pigment is lost from areas of the skin): 11 people, 18.64%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 10 people, 16.95%
Metastases To Bone (cancer spreads to bone): 9 people, 15.25%
Multiple Myeloma (cancer of the plasma cells): 3 people, 5.08%
Immunodeficiency Disorders: 3 people, 5.08%
Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 3 people, 5.08%
Lymphoma (cancer that begins in immune system cells): 1 person, 1.69%
Hiv Infection: 1 person, 1.69%
High Blood Pressure: 1 person, 1.69%
Depression: 1 person, 1.69%

* Approximation only. Some reports may have incomplete information.

Do you take Adriamycin pfs and have Conjunctivitis exacerbated?

- Check whether Conjunctivitis exacerbated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adriamycin pfs:

Adriamycin pfs (6,495 reports)

Browse all side effects of Adriamycin pfs:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Conjunctivitis exacerbated:

Conjunctivitis exacerbated (1,068 drugs)

Browse all the conditions that are associated with Conjunctivitis exacerbated:

Conjunctivitis exacerbated (426 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on doxorubicin hydrochloride (the active ingredients of Adriamycin pfs) and Adriamycin pfs (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.